<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187536</url>
  </required_header>
  <id_info>
    <org_study_id>502.341</org_study_id>
    <nct_id>NCT02187536</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics of Single Oral Doses of 40 mg Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan 80 mg Daily, Given Orally Over 6 Days. A Randomised, Placebo Controlled, Double Blind (for Telmisartan), Two Way Cross Over Trial in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics of simvastatin and simvastatin acid with/without concomitant
      administration of telmisartan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of simvastatin and simvastatin acid in plasma at different time points (AUC)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of simvastatin and simvastatin acid in plasma (Cmax)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax after a single extravascular dose (tmax)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life in plasma (t1/2)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance from plasma (CLtot/f)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of residence in the body (MRTtot)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/f)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of telmisartan at steady state (AUCss)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of telmisartan in plasma at steady state (Cmax,ss)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant findings in laboratory values</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant findings in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant findings in ECG</measure>
    <time_frame>Pre-dose, up to day 32 after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan combined with Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin and telmisartan placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan combined with Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>Telmisartan combined with Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin and telmisartan placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan placebo</intervention_name>
    <arm_group_label>Simvastatin and telmisartan placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by results of screening

          -  Signed written informed consent in accordance with good clinical practice (GCP) and
             local legislation

          -  Age ≥ 18 and ≤ 55 years

          -  Broca ≥ -20 % and ≤ +20 %

        Exclusion Criteria:

          -  Any findings of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastro-intestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Supine blood pressure at screening of systolic ≤ 110 mmHg and diastolic ≤ 60 mmHg

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infection

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half life (&gt; 24 hours) ≤ 1 month prior to administration
             or during the trial

          -  Use of any drugs which might influence the results of the trial (≤ 10 days prior to
             administration or during the trial)

          -  Participation in another trial with an investigational drug (30 days prior to
             administration or during the trial)

          -  Smoker

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation (≤ 1 month prior to administration or during the trial)

          -  Excessive physical activities (≤ 5 days prior to administration or during the trial)

          -  Any laboratory value outside the reference range of clinical relevance

          -  Hypersensitivity to telmisartan and/or simvastatin and/or related classes of drugs

        For female subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception (e.g. sterilization, intrauterine device (IUD), oral
             contraceptives)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

